Impact of complement activation on clinical outcomes in multiple sclerosis.


Journal

Annals of clinical and translational neurology
ISSN: 2328-9503
Titre abrégé: Ann Clin Transl Neurol
Pays: United States
ID NLM: 101623278

Informations de publication

Date de publication:
04 2021
Historique:
revised: 04 02 2021
received: 12 11 2020
accepted: 14 02 2021
pubmed: 2 3 2021
medline: 12 1 2022
entrez: 1 3 2021
Statut: ppublish

Résumé

We determined activation profiles of the classical and alternative complement pathway in 39 treatment-naïve patients with early relapse-onset MS. Plasma concentrations of complement fragments were unchanged in MS compared to 32 patients with non-inflammatory neurological diseases. Profiles in patients experiencing clinical exacerbations did not differ from patients with stable disease and did not correlate with baseline EDSS, numbers of T2 lesions and time to second relapse. Long-term EDSS outcomes 4 years after diagnosis did not significantly correlate with baseline complement levels. These data do not support the use of complement activation products as biomarkers for disease activity in early MS.

Identifiants

pubmed: 33646629
doi: 10.1002/acn3.51334
pmc: PMC8045986
doi:

Substances chimiques

Biomarkers 0
Complement System Proteins 9007-36-7

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

944-950

Informations de copyright

© 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.

Références

J Neurol Sci. 1998 May 7;157(2):168-74
pubmed: 9619641
Acta Neuropathol Commun. 2014 May 09;2:53
pubmed: 24887075
Mult Scler. 2017 Jun;23(7):946-955
pubmed: 27613120
Scand J Immunol. 2014 Feb;79(2):127-30
pubmed: 24313854
Immunity. 2020 Jan 14;52(1):167-182.e7
pubmed: 31883839
Brain. 2010 Jun;133(Pt 6):1602-11
pubmed: 20421219
Ann Neurol. 2008 Jan;63(1):16-25
pubmed: 18232012
J Neuroinflammation. 2016 Jun 22;13(1):161
pubmed: 27333900
Mult Scler. 2021 Apr;27(4):509-518
pubmed: 32669030
Mult Scler. 2012 Oct;18(10):1401-11
pubmed: 22354735
Brain. 2019 Sep 1;142(9):2722-2736
pubmed: 31289819

Auteurs

Christian W Keller (CW)

Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, 48149, Germany.

Johanna Oechtering (J)

Neurologic Clinic and Policlinic, Research Center for Clinical Neuroimmunology and Neuroscience Basel, University Hospital Basel, University of Basel, Basel, Switzerland.

Heinz Wiendl (H)

Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, 48149, Germany.

Ludwig Kappos (L)

Neurologic Clinic and Policlinic, Research Center for Clinical Neuroimmunology and Neuroscience Basel, University Hospital Basel, University of Basel, Basel, Switzerland.

Jens Kuhle (J)

Neurologic Clinic and Policlinic, Research Center for Clinical Neuroimmunology and Neuroscience Basel, University Hospital Basel, University of Basel, Basel, Switzerland.

Jan D Lünemann (JD)

Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, 48149, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH